As Redbiotec prepares for a Series A financing round to take the most advanced asset – immunotherapy for HSV2-associated genital herpes – into Phase I/IIa clinical trial, CEO Christian Schaub recently spoke with Mergermarket about company plans and visions.
Yao Cheng2020-03-26T09:53:39+01:00March 19th, 2020|
Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria
Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.